



Under the Paperwork Reduction Project 50680-6, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/553,661
		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
		Attorney Docket Number	50680-6
Sheet	1	of	11

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind code ² (if known)			
/AMG/	A1	US-4,806,463	02-21-1989	Goodchild et al.	
	A2	US-5,004,810	04-02-1991	Draper	
	A3	US-5,087,617	02-11-1992	Smith	
	A4	US-5,098,890	03-24-1992	Gewirtz et al.	
	A5	US-5,135,917	08-04-1992	Burch	
	A6	US-5,166,195	11-24-1992	Ecker	
	A7	US-5,194,428	03-16-1993	Agrawal et al.	
	A8	US-5,264,423	11-23-1993	Cohen et al.	
	A9	US-5,276,019	02-04-1994	Cohen et al.	
	A10	US-5,286,717	02-15-1994	Cohen et al.	
	A11	US-5,366,866	11-22-1994	Xu et al.	
	A11	US-5,484,704	01-16-1996	Dunbar	
	A12	US-5,645,995	07-08-1997	Kieback	
	A13	US-5,871,941	02-16-1999	Auersperg	
	A14	US-5,932,435	08-03-1999	Atkins et al.	
	A15	US-6,048,528	04-11-2000	Dunbar	
	A16	US-6,072,034	06-06-2000	Kaufman et al.	
	A17	US-6,277,563	08-21-2001	Shayesteh et al.	
	A18	US-6,300,492	10-09-2001	Korneluk et al.	
	A19	US-6,350,615	02-26-2002	Kaufman et al.	
	A20	US-6,376,654	04-23-2002	Gelber	
	A21	US-6,468,546	10-22-2002	Mitcham et al.	
	A22	US-6,468,758	10-22-2002	Benson et al.	
	A23	US-6,475,732	11-05-2002	Shayestah et al.	
	A24	US-6,488,931	12-03-2002	Mitcham et al.	
/AMG/	A25	US-6,512,102	01-28-2003	Xu et al.	

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/553,661
		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
Sheet 2 of 11	Attorney Docket Number	50680-6	

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁸
	Country Code ⁴ Number ⁴ Kind Code ⁵ (if known)					
	B1	WO 02/077023A2	10-03-2002	Universitat Zurich		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages, volume-issue number(s), publisher, city and /or country where published.	T ²
/AMG/	C1	Aasland R, Gibson TJ and Stewart AF. (1995). <i>Trends Biochem Sci</i> , 20, 56-59.	<input type="checkbox"/>
	C2	Aksan, I. & Stinson, J. A. (2002) <i>Trends Biochem. Sci.</i> 27, 387-389.	<input type="checkbox"/>
	C3	Amit, S. <i>et al.</i> Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. <i>Genes Dev.</i> 16, 1066-1076 (2002).	<input type="checkbox"/>
	C4	Baker BF, Condon TP, Koller E, McKay RA, Siwkowski AM, Vickers TA and Monia BP. (2001). <i>Methods</i> , 23, 191-198.	<input type="checkbox"/>
	C5	Belenkaya, T.Y. <i>et al.</i> pygopus Encodes a nuclear protein essential for wingless/Wnt signaling. <i>Development</i> 129, 4089-4101 (2002).	<input type="checkbox"/>
	C6	Bienz and Clevers. Cell 103: 311-320. Oct. 13, 2000	<input type="checkbox"/>
	C7	Brown AM. (2001). <i>Breast Cancer Res</i> , 3, 351-355.	<input type="checkbox"/>
/AMG/	C8	Cadigan, K. M. (2002) <i>Trends Genet.</i> 18, 340-342.	<input type="checkbox"/>

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/553,661
		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
		Attorney Docket Number	50680-6
Sheet	3	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages), volume-issue number(s), publisher, city and /or country where published.	T ²
/AMG/	C9	Chou, Y.Y. <i>et al.</i> Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. <i>Histopathology</i> 43, 151-156 (2003).	<input type="checkbox"/>
	C10	Clevers H. (2002). <i>Mol Cell</i> , 10, 1260-1261.	<input type="checkbox"/>
	C11	Cliffe, A., Hamada, F. & Bienz, M. (2003) <i>Curr. Biol.</i> 13, 960-966.	<input type="checkbox"/>
	C12	Coqueret O. (2002). <i>Gene</i> , 299, 35-55.	<input type="checkbox"/>
	C13	Davies, B. R., Worsley, S. D. & Ponder, B. A. (1998) <i>Histopathology</i> 32, 69-80.	<input type="checkbox"/>
	C14	Delcommenne M, Tan C, Gray V, Rue L, Woodgett J and Dedhar S. (1998). <i>Proc Natl Acad Sci U S A</i> , 95, 11211-11216.	<input type="checkbox"/>
	C15	Dhar, K. K., Branigan, K., Parkes, J., Howells, R. E., Hand, P., Musgrove, C., Strange, R. C., Fryer, A. A., Redman, C. W. & Hoban, P. R. (1999) <i>Br. J. Cancer</i> 81, 1174-1181.	<input type="checkbox"/>
	C16	Doble, B. W. & Woodgett, J. R. (2003) <i>J. Cell Sci.</i> 116, 1175-1186.	<input type="checkbox"/>
	C17	Fanto, M. & McNeill, H. Planar polarity from flies to vertebrates. <i>J. Cell Sci.</i> 117, 527-533 (2004).	<input type="checkbox"/>
	C18	Furuuchi K, Tada M, Yamada H, Kataoka A, Furuuchi N, Hamada J, Takahashi M, Todo S and Moriuchi T. (2000). <i>Am J Pathol</i> , 156, 1997-2005.	<input type="checkbox"/>
/AMG/	C19	Gao, Z.H., Seeling, J.M., Hill, V., Yochum, A., & Virshup, D.M. Casein kinase I phosphorylates and destabilizes the beta-catenin degradation complex. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 99, 1182-1187 (2002).	<input type="checkbox"/>

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/553,661
		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
Sheet 4	of 11	Attorney Docket Number	50680-6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages, volume-issue number(s), publisher, city and /or country where published.	T ²
/AMG/	C20	Giles RH, van Es JH and Clevers H. (2003). <i>Biochim Biophys Acta</i> , 1653, 1-24.	<input type="checkbox"/>
	C21	Greaves. <i>Nature Cell Biol.</i> 4:E124. May 2002	<input type="checkbox"/>
	C22	Green DW, Roh H, Pippin J and Drebin JA. (2000). <i>J Am Coll Surg</i> , 191, 93-105.	<input type="checkbox"/>
	C23	He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW. (1998). <i>Science</i> , 281, 1509-1512.	<input type="checkbox"/>
	C24	Henderson, B.R. Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. <i>Nat. Cell Biol.</i> 2, 653-660 (2000).	<input type="checkbox"/>
	C25	Holthoner W, Pillinger M, Groger M, Wolff K, Ashton AW, Albanese C, Neumeister P, Pestell RG and Petzelbauer P. (2002). <i>J Biol Chem</i> , 277, 45847-45853.	<input type="checkbox"/>
	C26	Howe LR and Brown AM. (2004). <i>Cancer Biol Ther</i> , 3: 36-41	<input type="checkbox"/>
	C27	Huelsken, J. & Behrens, J. The Wnt signalling pathway. <i>J. Cell Sci.</i> 115, 3977-3978 (2002).	<input type="checkbox"/>
	C28	http://www2.mrc-lmb.cam.ac.uk/research/CB/Bienz.M/BienzM.html [2 page print-out] 2006	<input type="checkbox"/>
	C29	Ju ST, Panka DJ, Cui H, Ettinger R, el Khatib M, Sherr DH, Stanger BZ and Marshak-Rothstein A. (1995). <i>Nature</i> , 373, 444-448.	<input type="checkbox"/>
	C30	Kikuchi, A. (2003) <i>Cancer Sci.</i> 94, 225-229.	<input type="checkbox"/>
/AMG/	C31	Kishida S, Yamamoto H, Hino S, Ikeda S, Kishida M and Kikuchi A. (1999). <i>Mol Cell Biol</i> , 19, 4414-4422.	<input type="checkbox"/>

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/553,661
		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
Sheet 5	of 11	Attorney Docket Number	50680-6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages, volume-issue number(s), publisher, city and /or country where published.	T ²
/AMG/ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	C32	Kishida, S. <i>et al.</i> Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. <i>J. Biol. Chem.</i> 273, 10823-10826 (1998).	<input type="checkbox"/>
	C33	Klingensmith J, Nusse R and Perrimon N. (1994). <i>Genes Dev</i> , 8, 118-130.	<input type="checkbox"/>
	C34	Korinek et al. <i>Science</i> 275: 1784-1787. 1997.	<input type="checkbox"/>
	C35	Kramps, T. <i>et al.</i> Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. <i>Cell</i> 109, 47-60 (2002).	<input type="checkbox"/>
	C36	Kuhl, M. The WNT/Calcium pathway: biochemical mediators, tools and future requirements. <i>Front Biosci.</i> 9, 967-974 (2004).	<input type="checkbox"/>
	C37	Kuhnert, F. <i>et al.</i> Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 101, 266-271 (2004).	<input type="checkbox"/>
	C38	Lake BB and Kao KR. (2003). <i>Dev Biol</i> , 261, 132-148.	<input type="checkbox"/>
	C39	Lake et al. <i>Development</i> . 128(2): 263-273. January 2001 (Abstract)	<input type="checkbox"/>
	C40	Lepourcelet, M., Chen, Y. N., France, D. S., Wang, H., Crews, P., Petersen, F., Bruseo, C., Wood, A. W. & Shivdasani, R. A. (2004) <i>Cancer Cell</i> 5, 91-102.	<input type="checkbox"/>
	C41	Li, Y. <i>et al.</i> Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. <i>Proc. Natl. Acad. Sci. U. S. A</i> 100, 15853-15858 (2003).	<input type="checkbox"/>
/AMG/	C42	Li, H., Pamukcu, R. & Thompson, W. J. (2002) <i>Cancer Biol. Ther.</i> 1, 621-625.	<input type="checkbox"/>

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/553,661
		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
Sheet 6	of 11	Attorney Docket Number	50680-6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages, volume-issue number(s), publisher, city and /or country where published.	T ²
/AMG/	C43	Lim SC and Lee MS. (2002). <i>Oncol Rep</i> , 9, 915-928.	<input type="checkbox"/>
	C44	Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG and Hung MC. (2000). <i>Proc Natl Acad Sci U S A</i> , 97, 4262-4266.	<input type="checkbox"/>
	C45	Lustig B and Behrens J. (2003). <i>J Cancer Res Clin Oncol</i> , 129, 199-221.	<input type="checkbox"/>
	C46	Miller, J.R., Hocking, A.M., Brown, J.D., & Moon, R.T. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. <i>Oncogene</i> 18, 7860-7872 (1999).	<input type="checkbox"/>
	C47	Moon, R.T., Bowerman, B., Boutros, M., & Perrimon, N. The promise and perils of Wnt signaling through beta-catenin. <i>Science</i> 296, 1644-1646 (2002).	<input type="checkbox"/>
	C48	Muratovska A, Zhou C, He S, Goodyer P and Eccles MR. (2003). <i>Oncogene</i> , 22, 7989-7997.	<input type="checkbox"/>
	C49	Nagahata T, Shimada T, Harada A, Nagai H, Onda M, Yokoyama S, Shiba T, Jin E, Kawanami O and Emi M. (2003). <i>Cancer Sci</i> , 94, 515-518.	<input type="checkbox"/>
↓	C50	NCBI Sequence Accession No. AY141128 Lake and Kao. Oct. 21, 2002.	<input type="checkbox"/>
/AMG/	C51	NCBI Sequence Accession NO. AY141129 Lake and Kao. Oct, 21, 2002.	<input type="checkbox"/>

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/553,661
		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
		Attorney Docket Number	50680-6
Sheet	7	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages, volume-issue number(s), publisher, city and /or country where published.	T ²
/AMG/	C52	NCBI Sequence Accession No. AF521655 Belenkaya et al. Aug. 14, 2002.	<input type="checkbox"/>
	C53	NCBI Sequence Accession No. AAM94597 Belenkaya et al. Aug. 14, 2002.	<input type="checkbox"/>
	C54	Nusse R and Varmus HE. (1982). <i>Cell</i> , 31, 99-109.	<input type="checkbox"/>
	C55	Orsulic, S., Huber, O., Aberle, H., Arnold, S., & Kemler, R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. <i>J. Cell Sci.</i> 112 (Pt 8), 1237-1245 (1999).	<input type="checkbox"/>
	C56	Palacios, J. & Gamallo, C. (1998) <i>Cancer Res.</i> 58, 1344-1347.	<input type="checkbox"/>
	C57	Parker, D.S., Jemison, J., & Cadigan, K.M. Pygopus, a nuclear PHD-finger protein required for Wingless signaling in Drosophila. <i>Development</i> 129, 2565-2576 (2002).	<input type="checkbox"/>
	C58	Polakis P. (2000). <i>Genes Dev</i> , 14, 1837-1851.	<input type="checkbox"/>
	C59	Polesskaya, A., Seale, P., & Rudnicki, M.A. Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. <i>Cell</i> 113, 841-852 (2003).	<input type="checkbox"/>
	C60	Qin C, Burghardt R, Smith R, Wormke M, Stewart J and Safe S. (2003). <i>Cancer Res</i> , 63, 958-964.	<input type="checkbox"/>
/AMG/	C61	Rask, K. et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. <i>Br. J. Cancer</i> 89, 1298-1304 (2003).	<input type="checkbox"/>

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/553,661
		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
Sheet 8	of 11	Attorney Docket Number	50680-6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages), volume-issue number(s), publisher, city and /or country where published.	T ²
/AMG/	C62	Reynolds, J.N., Prasad, A., Gillespie, L.L., & Paterno, G.D. Developmental expression of functional GABAA receptors containing the gamma 2 subunit in neurons derived from embryonal carcinoma (P19) cells. <i>Brain Res. Mol. Brain Res.</i> 35, 11-18 (1996).	<input type="checkbox"/>
	C63	Rorke, S., Murphy, S., Khalifa, M., Chemenko, G., & Tang, S.C. Prognostic significance of BAG-1 expression in nonsmall cell lung cancer. <i>Int. J. Cancer</i> 95, 317-322 (2001).	<input type="checkbox"/>
	C64	Ryan PJ and Gillespie LL. (1994). <i>Dev Biol</i> , 166, 101-111.	<input type="checkbox"/>
	C65	Ryo A, Nakamura M, Wulf G, Liou YC and Lu KP. (2001). <i>Nat Cell Biol</i> , 3, 793-801.	<input type="checkbox"/>
	C66	Scholten, A.N., Creutzberg, C.L., van den Broek, L.J., Noordijk, E.M., & Smit, V.T. Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. <i>J. Pathol.</i> 201, 460-465 (2003).	<input type="checkbox"/>
	C67	Schwartz, D.R. et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. <i>Cancer Res.</i> 63, 2913-2922 (2003).	<input type="checkbox"/>
	C68	Seidman, J.D. & Kurman, R.J. Pathology of ovarian carcinoma. <i>Hematol. Oncol. Clin. North Am.</i> 17, 909-25, vii (2003).	<input type="checkbox"/>
	C69	Sekiya T, Nakamura T, Kazuki Y, Oshimura M, Kohu K, Tago K, Ohwada S and Akiyama T. (2002). <i>Cancer Res</i> , 62, 3322-3326.	<input type="checkbox"/>
	C70	Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Oku N, Miyazawa K, Kitamura N, Takeichi M and Ito F. (1994). <i>Cell Adhes Commun</i> , 1, 295-305.	<input type="checkbox"/>
/AMG/	C71	Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R and Ben Ze'ev A. (1999). <i>Proc Natl Acad Sci U S A</i> , 96, 5522-5527.	<input type="checkbox"/>

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
		Application Number	10/553,661
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
		Attorney Docket Number	50680-6
Sheet	9	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages, volume-issue number(s), publisher, city and/or country where published.	T ²
/AMG/	C72	Smalley MJ and Dale TC. (2001). <i>J Mammary Gland Biol Neoplasia</i> , 6, 37-52.	<input type="checkbox"/>
	C73	Taipale J and Beachy PA. (2001). <i>Nature</i> , 411, 349-354.	<input type="checkbox"/>
	C74	Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP and He X. (2000). <i>Nature</i> , 407, 530-535.	<input type="checkbox"/>
	C75	Tetsu O and McCormick F. (1999). <i>Nature</i> , 398, 422-426.	<input type="checkbox"/>
	C76	Thompson B, Townsley F, Rosin-Arbesfeld R, Musisi H and Bienz M. (2002). <i>Nat Cell Biol</i> , 4, 367-373.	<input type="checkbox"/>
	C77	Thompson BJ. (2004). <i>Curr Biol</i> , 14, 458-466.	<input type="checkbox"/>
	C78	Townsley FM, Thompson B and Bienz M. (2004). <i>J Biol Chem</i> , 279, 5177-5183.	<input type="checkbox"/>
	C79	Townsley FM, Cliffe A and Bienz M. (2004). <i>Nat Cell Biol</i> , 6, 626-633.	<input type="checkbox"/>
	C80	Tsutsumi K, Belaguli N, Qi S, Michalak TI, Gulliver WP, Pater A and Pater MM. (1992). <i>Am J Pathol</i> , 140, 255-261.	<input type="checkbox"/>
↓	C81	van De WM, Barker N, Harkes IC, van der HM, Dijk NJ, Hollestelle A, Klijn JG, Clevers H and Schutte M. (2001). <i>Cancer Res</i> , 61, 278-284.	<input type="checkbox"/>
/AMG/	C82	van De WM, Cavallo R, Dooijes D, van Beest M, van Es J, Loureiro J, Ypma A, Hursh D, Jones T, Bejsovec A, Peifer M, Mortin M and Clevers H. (1997). <i>Cell</i> , 88, 789-799.	<input type="checkbox"/>

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/553,661
		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
Sheet 10	of 11	Attorney Docket Number 50680-6	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages, volume-issue number(s), publisher, city and /or country where published.	T ²
/AMG/	C83	Verma,U.N., Surabhi,R.M., Schmalstieg,A., Becerra,C., & Gaynor,R.B. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. <i>Clin. Cancer Res.</i> 9, 1291-1300 (2003).	<input type="checkbox"/>
	C84	Watts CK, Sweeney KJ, Warlters A, Musgrove EA and Sutherland RL. (1994). <i>Breast Cancer Res Treat</i> , 31, 95-105.	<input type="checkbox"/>
	C85	Webster MT, Rozycka M, Sara E, Davis E, Smalley M, Young N, Dale TC and Wooster R. (2000). <i>Genes Chromosomes Cancer</i> , 28, 443-453.	<input type="checkbox"/>
	C86	Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, Schejter E, Tomlinson A and DiNardo S. (2000). <i>Nature</i> , 407, 527-530.	<input type="checkbox"/>
	C87	Wheelock, M.J. & Johnson,K.R. Cadherins as modulators of cellular phenotype. <i>Annu. Rev. Cell Dev. Biol.</i> 19, 207-235 (2003).	<input type="checkbox"/>
	C88	Wheelock MJ and Knudsen KA. (1991). <i>In Vivo</i> , 5, 505-513.	<input type="checkbox"/>
	C89	Wiggan,O. & Hamel,P.A. Pax3 regulates morphogenetic cell behavior in vitro coincident with activation of a PCP/non-canonical Wnt-signaling cascade. <i>J. Cell Sci.</i> 115, 531-541 (2002).	<input type="checkbox"/>
	C90	Willert,K., Shibamoto,S., & Nusse,R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. <i>Genes Dev.</i> 13, 1768-1773 (1999).	<input type="checkbox"/>
/AMG/	C91	Willis TG, Zalcborg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, Bastard C, Treleaven JG, Catovsky D, Silva ML and Dyer MJ. (1998). <i>Blood</i> , 91, 1873-1881.	<input type="checkbox"/>

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
		Application Number	10/553,661
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	October 17, 2005
		First Named Inventor	Kenneth Kao et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
		Attorney Docket Number	50680-6
Sheet	11	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages), volume-issue number(s), publisher, city and /or country where published.	T ²
/AMG/	C92	Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoeck R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A and Pilarsky C. (2003). <i>J Pathol</i> , 201 , 204-212.	<input type="checkbox"/>
	C93	Wong, A.S. & Auersperg, N. Ovarian surface epithelium: family history and early events in ovarian cancer. <i>Reprod. Biol. Endocrinol.</i> 1 , 70 (2003).	<input type="checkbox"/>
	C94	Yam CH, Fung TK and Poon RY. (2002). <i>Cell Mol Life Sci</i> , 59 , 1317-1326.	<input type="checkbox"/>
	C95	Yanagawa S, van Leeuwen F, Wodarz A, Klingensmith J and Nusse R. (1995). <i>Genes Dev</i> , 9 , 1087-1097.	<input type="checkbox"/>
	C96	Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, Van Herle AJ and Law RE. (2001). <i>Biochem Biophys Res Commun</i> , 286 , 916-922.	<input type="checkbox"/>
	C97	Zhai, Y. et al. Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. <i>Am. J. Pathol.</i> 160 , 1229-1238 (2002).	<input type="checkbox"/>
/AMG/	C98	Zhurinsky, J., Shtutman, M. & Ben Ze'ev, A. (2000) <i>J. Cell Sci.</i> 113 (Pt 18) , 3127-3139.	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature	/Anne Gussow/	Date Considered	03/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.